Company
In animal models, our drugs survive longer in blood and in cancer cells to enable tumor destruction with a single dose compared with current solutions.
Our Path to Success
- Intravenous (IV) delivery
- High survivability in tumors and blood
- Induction of optimum anti-tumor immune response
- Effective against metastatic tumors
- No virus has failed clinical toxicity studies
300
Total patent claims
30
Years of oncolytic virus research
3
Generation of proven virus technology
Decades of expertise in biotech and cancer therapeutics:
